« Return to News | Technology Solutions | CROs/Service Providers

BioClinica inks seven with Trident IWR

Monday, April 18, 2011 11:55 AM

Pennsylvania-based BioClinica, a provider of clinical trial management solutions, has been selected by seven new clients for the use of BioClinica’s Trident IWR (interactive web response) to help build and deploy clinical trials without the need for programming.

Trident IWR provides clinical operations personnel a way to set up, monitor, and maintain randomization and supplies for their clinical trials, in a cost-efficient and timely manner. Trident IWR does not require programming for each new clinical trial, and it configures both web and voice at the same time, potentially initiating the study start time faster.

GlaxoSmithKline signed an agreement with BioClinica to standardize on the Trident IWR system, selecting the technology as a way to manage their global trials across phase I-IV clinical trials.

Mark Weinstein, CEO of BioClinica, stated: “With seven companies making the decision to standardize their complex trials with Trident IWR in just the first quarter of 2011 alone, we are happy to confirm that our best-in-class solution is successfully providing the efficiencies, cost savings and overall support needed by today’s top pharmaceutical companies.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.